InspireMD Inc. (NSPR)

In the past six months, InspireMD reported its Third Quarter 2025 Financial Results, with total revenue increasing by 39% year-over-year. The company welcomed the publication of the CREST-2 trial in the New England Journal of Medicine. InspireMD announced the publication of the C-GUARDIANS Pivotal Trial manuscript in the Journal of the American College of Cardiology (JACC). InspireMD announced inducement grants under Nasdaq Listing Rule 5635(c)(4). InspireMD reported its Fourth Quarter and Full Year 2025 Financial Results, with a 62% year-over-year increase in Q4 2025 revenue. InspireMD launched an "at the market" (ATM) program with BTIG as an agent. InspireMD requested shareholders to approve an increase in authorized shares. InspireMD is scheduled to participate in the 25th Annual Needham Virtual Healthcare Conference. Over the past 12 months, the stock has experienced a decline.

There is no explicit information detailing the demand seasonality for InspireMD, Inc.'s specific products and services. Demand for its products is likely driven more by medical necessity, disease prevalence, and healthcare system capacity rather than typical seasonal consumer trends.

InspireMD, Inc. is a medical device company focused on developing and commercializing solutions for stroke prevention and the treatment of complex vascular and coronary diseases. The company's core innovation is its MicroNet™ mesh platform technology, a nanostructured covering designed to prevent embolic events during stent implantation. Its major products include the CGuard® Prime Carotid Stent System, CGuard® Carotid Embolic Prevention System (EPS), MGuard Prime Embolic Protection System (MGuard Prime EPS), and SwitchGuard NPS. The company aims to establish its products as the industry standard for carotid stenting.

InspireMD, Inc. is headquartered in Miami, Florida, with international operations in Tel Aviv, Israel. The company has an established international presence, with its products commercially available in multiple international markets. InspireMD sells its products through local distribution partners across Europe, Latin America, the Middle East, and Asia Pacific, including countries such as Italy, Germany, Russia, Poland, Australia, New Zealand, Vietnam, Hong Kong, and Taiwan.

InspireMD's brand reputation has been positively influenced by significant clinical and regulatory achievements. The company's CGuard® Prime carotid stent system received FDA premarket approval in June 2025, followed by its U.S. commercial launch in July 2025. The C-GUARDIANS pivotal trial results for the CGuard® Prime carotid stent system were published in the Journal of the American College of Cardiology (JACC). InspireMD highlighted the supportive external clinical evidence from the CREST-2 study, published in the New England Journal of Medicine.

InspireMD stock is owned by a mix of institutional shareholders and company insiders. Institutional shareholders hold 49.51% of the stock, while InspireMD insiders own 59.03%. Major institutional owners include Rosalind Advisors, Inc., Nantahala Capital Management, LLC, Standard Life Aberdeen plc, Orbimed Advisors Llc, Parkman Healthcare Partners LLC, Velan Capital Investment Management LP, Marshall Wace, Llp, Soleus Capital Management, L.P., Pura Vida Investments, Llc and Ingalls & Snyder Llc. Ofir Paz is the largest individual InspireMD shareholder.